Compare Huntington Bancshares Incorporated (HBAN) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Heron Therapeutics Inc — how do they compare? Huntington Bancshares Incorporated trades at $17.85 (market cap $35.93B), while Heron Therapeutics Inc trades at $0.34 (market cap $61.47M). The key difference: Huntington Bancshares Incorporated is far larger — about 584.5× Heron Therapeutics Inc's market cap, and Huntington Bancshares Incorporated pays a 3.49% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HBAN | HRTX | |
|---|---|---|
Market Cap | $35.93B | $61.47M |
Sector | Financials | Health |
52-Week High | $19.27 | $1.49 |
52-Week Low | $15.02 | $0.32 |
Dividend Yield | 3.49% | — |
Enterprise Value | — | $168.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $17.82, up 1.25% recently, with a bullish technical outlook and mixed earnings history. The company reported Q2 2026 EPS of $0.33, missing estimates, but revenue growth to $8.13B in 2025 supports a net income margin of 24.77%. Analysts maintain a consensus price target of $19.78, with 45% recommending Buy, amid concerns over rising deposit costs noted in recent news.
HBAN offers potential upside with a reasonable P/E of 13.68 and dividend yield, but faces risks from expense pressures and competitive banking dynamics. The stock's outlook hinges on execution of its ROTCE target of 18-19% by 2027, balancing growth opportunities with macroeconomic headwinds.
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
